688315.SH
Novogene Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 19.50
+15.80%Year over year
Reported trailing growth
- Revenue
- +5.6%
- EBITDA
- —
- EBIT
- -19.6%
- EPS
- -19.9%
- Free cash flow
- -33.9%
- Operating cash flow
- -28.8%
Forward estimates
Based on analyst estimates
- Revenue
- -6.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.7%
- EBITDA
- -0.4%
- EBIT
- -3.1%
- Net income
- -2.0%
- EPS
- -2.3%
- Free cash flow
- +9.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026